MCAM, MMP-2, and Gal-3 expression in primary melanoma have been linked to poorer overall survival (89, 90, 144, 206, 207) and could be used in combination with current prognostic indicators to identify patients at high-risk of recurrence (Figure 2). Here, LGALS3 is linked to melanoma.